Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of a bivalent norovirus VLP vaccine with or without MPL and aluminum hydroxide in adolescents and adults
2013-001419-64Phase 2Completed
- Sponsor
- Takeda Vaccines
- Start
- Dec 2013
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human norovirus bivalent (GI.1/GII.4) vaccine in Noroviral gastroenteritis (2 arms), sponsored by Takeda Vaccines. Primary endpoint: Immunogenicity. Started Dec 2013; status: completed.
02
Drugs
human norovirus bivalent (GI.1/GII.4) vaccine
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on 2013-001419-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001419-64.